Gilead’s coronavirus treatment remdesivir to cost $3,120 for U.S. insured patients

Gilead’s coronavirus treatment remdesivir to cost $3,120 per U.S. patient with private insurance

The drugmaker said it will sell remdesivir for $390 per vial to governments “of developed countries” around the world, and the price for U.S. private insurance companies will stand at $520 per vial. In the U.S., that means Gilead will charge a lower price for government programs like Medicare and a higher price for privately insured people.

Wonder how many insurance companies will approve it?!

COVID-19 and the High Cost of Dying

COVID-19 and the High Cost of Dying

If the FDA approves remdesivir for treating Covid-19, which is by no means guaranteed, Gilead will be able to charge what it likes until 2037. Until then, you can forget about a cheap generic version of the drug.

Related:

Joe Grogan, Trump’s Top Domestic Policy Aide, Leaving White House Next Month

Grogan — who worked as a lobbyist for drugmaker Gilead prior to his time at the White House — has played a significant role in crafting major health policies, including drug pricing, for the Trump administration.